ゲノム編集の決定版ガイド。
メニュー
ホーム 学ぶ ニュース Atlasに聞く
探索する 技術 疾患 治療法 臨床試験 企業 科学者 遺伝子 研究 研究機関
医療を超えて 農業 倫理 投資 世界地図
学ぶ・ツール まずはここから 用語集 A~Z 技術を比較する タイムライン リスト・ランキング AIエージェント ★ 保存済み API
このサイトについて 私たちについて 方法論 データソース 編集方針 お問い合わせ 免責事項

🧭 ガイドビュー
遺伝学が初めてですか? 閲覧しながら、すべての用語をわかりやすく説明します。同じページに、サポートが組み込まれています。

⚡ 専門家の見解
生物学はすでにご存知の方へ。コンテンツだけをすっきりとコンパクトに、余分な説明なしでお届けします。これがデフォルト表示です。

表示言語
ライトモード

Disease · Neurological disease

Huntington's Disease

A fatal inherited brain disease caused by a toxic protein — where the genetics are unusually clear and the delivery problem is unusually hard.

Preclinical braindelivery problemHTT
Preclinical research Tested in cells and animals only. Most preclinical programmes never reach people, and animal results often do not carry over.

わかりやすい説明

A repeated stretch of DNA in one gene becomes too long, and the protein it makes gains a new, harmful property that slowly kills brain cells controlling movement, thinking and mood. The genetics could not be clearer: inherit the expansion and you will develop the disease. What is not clear is how to get an editing machine into billions of neurons, spread throughout the brain, behind a barrier evolved specifically to keep things out.

さらに深く掘り下げる

Huntington's disease is caused by CAG repeat expansion in HTT, producing mutant huntingtin with a toxic gain of function; it is autosomal dominant with essentially complete penetrance above about 40 repeats. Because the pathology is gain-of-function, silencing or removing the mutant allele is the therapeutic goal — ideally allele-selectively, since wild-type huntingtin has essential functions. Delivery across the blood-brain barrier to sufficient neurons remains unsolved, and the fact that neurons do not divide means homology-directed repair is unavailable.

Two hard problems, not one

Delivery is the obvious one. The less obvious one is selectivity: everyone with Huntington's has one normal copy of the gene and one expanded copy, and the normal copy does something important. A treatment that silences both may create a new problem while solving the old one, so allele-selective approaches — targeting variants that happen to sit on the expanded copy — are an active area.

Non-editing approaches to lowering huntingtin have had a difficult clinical history, which has made the whole field appropriately cautious about this target.

Two hard problems, not one
A neuron with an aggregate of misfolded protein in its cell body. Illustration generated for The CRISPR Atlas — a visual aid, not a photograph or a literal depiction of molecular structure.

Sources

Connected in the Atlas

Every entry on this site is linked to the others it relates to. These connections are part of the record, not a search result.

Technologies

CRISPR-Cas13

Genes

HTT
教育目的の情報のみ このページはリファレンスであり、医療上のアドバイスではありません。研究・規制上のステータスは変わることがあります。上記の最終更新日を確認し、重要な情報は記載の一次情報源で必ずご確認ください。